Immunophenotype
| . | SPTL-AB . | SPTL-GD (CGD-TCL) . | P . |
|---|---|---|---|
| CD3 | 59/62 (95) | 16/19 (84) | ns |
| CD4 | 0/61 (0) | 1/18 (5) | ns |
| CD8 | 60/63 (95) | 2/20 (10) | < .001 |
| CD30 | 0/45 (0) | 3/19 (16) | .02 |
| CD56 | 0/61 (0) | 12/20 (60) | < .001 |
| Cytotoxic proteins† | 63/63 (100) | 19/19 (100) | ns |
| βF1 | 52/57 (91) | 0/20 (0) | < .001 |
| TCRδ | 0/10 (0) | 6/6 (100) | < .001 |
| Mib-1 | 36/53 (70) | 12/14 (85) | ns |
| EBER | 0/38 (0) | 0/15 (0) | ns |
| Clonal TCRβ | 9/9 (100) | ND | ns |
| Clonal TCRγ | 28/36 (78) | 10/12 (83) | ns |
| . | SPTL-AB . | SPTL-GD (CGD-TCL) . | P . |
|---|---|---|---|
| CD3 | 59/62 (95) | 16/19 (84) | ns |
| CD4 | 0/61 (0) | 1/18 (5) | ns |
| CD8 | 60/63 (95) | 2/20 (10) | < .001 |
| CD30 | 0/45 (0) | 3/19 (16) | .02 |
| CD56 | 0/61 (0) | 12/20 (60) | < .001 |
| Cytotoxic proteins† | 63/63 (100) | 19/19 (100) | ns |
| βF1 | 52/57 (91) | 0/20 (0) | < .001 |
| TCRδ | 0/10 (0) | 6/6 (100) | < .001 |
| Mib-1 | 36/53 (70) | 12/14 (85) | ns |
| EBER | 0/38 (0) | 0/15 (0) | ns |
| Clonal TCRβ | 9/9 (100) | ND | ns |
| Clonal TCRγ | 28/36 (78) | 10/12 (83) | ns |
Data are numbers of cases with more than 50% positive tumor cells/total number of cases studied (%) unless otherwise indicated.
ND indicates not done; and ns, not significant.
Data are expression of granzyme B, TIA-1, and/or perforin.